Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 | Anagrelide capsules | ||
| Avatrombopag (Doptelet®) | ||
| Cyanocobalamin tablets | ||
| Darbepoetin alfa (Aranesp) | NHSE commissioned renal dialysis. CCG commissioned for use in cancer - NICE TA323. | |
| Deferasirox (Exjade) | ||
| Deferiprone tablets (Ferriprox) | NHSE commissioned. | |
| Desferrioxamine injection | NHSE commissioned - NICE NG8. | |
| Eltrombopag tablets | ||
| Epoetin beta syringe (Neorecormon) | NHSE commissioned renal dialysis. CCG Commissioned for use in cancer - NICE TA323. | |
| Fanhdi® | ||
| Ferric carboxymaltose injection (Ferinject) | ||
 | Ferric maltol (Feraccru®) | For the treatment of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD), unable to tolerate other oral iron formulations. Supported by a RICaD | |
 | Ferrous fumarate liquid | ||
| Ferrous fumarate tablets | ||
| Ferrous gluconate tablets | If patient intolerant of sulphate. | |
| Ferrous sulphate tablets | High relative cost. | |
| Filgastrim injection | ||
| Folic acid SF solution (Lexpex) | ||
| Folic acid tablets | ||
| Fostamatinib (Tavlesse®) | ||
| Hydroxocobalamin injection | ||
| Hydroxycarbamide capsules | For use in sickle cell. | |
 | Iron (III) isomaltoside 1000 (Diafer) | Under review. | |
| Iron isomaltoside 1000 (Monofer) | ||
| Iron-hydroxide sucrose complex injection (Venofer) | ||
| Lenograstim injection | ||
| Lusutrombopag (Mulpleo®) | ||
| Methoxy polyethelene glycol-epoetin beta (Mircera) | NHSE commissioned renal dialysis. CCG commissioned for use in cancer - NICE TA323. | |
| Pegfilgrastim injection | QEHB site only | |
| Pregaday tablets | ||
| Ravulizumab (Ultomiris®) | ||
| Romiplostim injection | ||
| Sodium feredetate SF elixir |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
